Arcturus Therapeutics (ARCT) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Outperform | $19.00 from $13.00 | Oct 9, 2026 |
| BTIG | Maintained | Buy | $20.00 from $23.00 | Sep 24, 2026 |
| Citigroup | Upgraded | Neutral → Buy | $20.00 from $8.00 | Sep 24, 2026 |
| Freedom Broker | Initiated Coverage | Buy | $27.00 | Jul 2, 2026 |
| B. Riley Securities | Initiated Coverage | Neutral → Buy | $22.00 | Mar 18, 2026 |
| Citigroup | Maintained | Buy | $21.00 from $66.00 | Mar 5, 2026 |
| Piper Sandler | Maintained | Overweight | $25.00 from $72.00 | Mar 4, 2026 |
| Citigroup | Maintained | Neutral | $8.00 from $7.00 | Mar 4, 2026 |
| Citigroup | Maintained | Neutral | $7.00 from $9.00 | Jan 6, 2026 |
| Citigroup | Maintained | Neutral | $9.00 from $12.00 | Nov 13, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $9.00 from $12.00 | Nov 11, 2025 |
| Piper Sandler | Maintained | Overweight | $72.00 from $140.00 | Nov 11, 2025 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | $12.00 from $60.00 | Oct 24, 2025 |
| Guggenheim | Downgraded | Buy → Neutral | — | Oct 23, 2025 |
| Wells Fargo | Maintained | Overweight | $20.00 from $42.00 | Oct 23, 2025 |
| Citigroup | Downgraded | Buy → Neutral | $12.00 from $49.00 | Oct 23, 2025 |
| Guggenheim | Downgraded | Buy → Neutral | — | Oct 22, 2025 |
| BTIG | Maintained | Buy | $23.00 from $48.00 | Oct 22, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $60.00 | Sep 4, 2025 |
| Leerink Partners | Maintained | Outperform | $54.00 from $63.00 | Aug 22, 2025 |
Frequently asked questions
What is the price target for ARCT stock?
The average 12-month analyst price target for Arcturus Therapeutics (ARCT) is $19.67, with a high estimate of $20.00 and a low of $19.00, across 3 analysts.
Is ARCT a buy, sell, or hold?
Analysts covering Arcturus Therapeutics currently average a Buy rating: 11 buy, 2 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ARCT?
The average price target of $19.67 implies 76.86% upside from the last price of $11.12.
What is the latest analyst rating on ARCT?
On Oct 9, 2026, Leerink Partners maintained Arcturus Therapeutics at Outperform with a price target of $19.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.